Therapy for ankylosing spondylitis: new treatment modalities

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Therapeutic options for severe spondyloarthritis (SpA) have been limited.
• Anti-tumour necrosis factor (anti-TNF) therapy demonstrates significant efficacy in SpA, particularly ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
• Existing disease-modifying anti-rheumatic drugs are not available for severely affected AS patients, creating an unmet medical need.

Purpose of the Study:

• To evaluate the efficacy of anti-TNF therapy in patients with severe spondyloarthritis (SpA).
• To compare the effectiveness of anti-TNF agents in SpA versus rheumatoid arthritis (RA).
• To assess the potential of TNF blockers as a first-line treatment for active AS.

Main Methods:

• Analysis of data from over 200 AS patients and 100 PsA patients treated with anti-TNF agents.
• Review of clinical trial data for infliximab (Remicade) and etanercept (Enbrel) in SpA.
• Consideration of dosing regimens and treatment intervals for optimal disease suppression.

Main Results:

• Anti-TNF therapy, including infliximab and etanercept, is highly effective in AS and PsA, potentially exceeding its efficacy in RA.
• Infliximab at 5mg/kg with 6-12 week intervals shows sustained disease activity suppression.
• Etanercept demonstrated efficacy in PsA and AS, with preliminary evidence of benefit in other SpA subtypes.

Conclusions:

• Anti-TNF therapy represents a promising treatment for severe SpA, addressing an unmet medical need.
• TNF blockers may be considered first-line therapy for active AS unresponsive to NSAIDs.
• Further long-term studies are required to confirm sustained efficacy, safety, and impact on radiological progression.